title: Pancreatic adenocarcinoma.
authors.affiliation: From the Division of Hematology-Oncology, Department of Medicine (D.P.R., N.B.), and the Department of Radiation Oncology (T.S.H.), Massachusetts General Hospital, Boston.
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
authors.forename: Theodore S
authors.initials: TS
authors.lastname: Hong
authors.forename: Nabeel
authors.initials: N
authors.lastname: Bardeesy
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D006801:Humans; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D012307:Risk Factors; D018631:ras Proteins / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins